There were 715 press releases posted in the last 24 hours and 155,017 in the last 365 days.

Global Orphan Drugs Market Report 2019-2024 Featuring Teva Pharmaceutical, Celgene, Merck & Co, Bristol-Myers Squibb, and F. Hoffmann-La Roche

/EIN News/ -- Dublin, May 17, 2019 (GLOBE NEWSWIRE) -- The "Orphan Drugs Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

The orphan drugs market is expected to register a CAGR of 11.5% over the forecast period

Factors that are responsible for the growth of this market include market exclusivity for orphan drug developers, the rising prevalence of rare diseases, and favorable government policies.

The market is expected to register an increased CAGR during the forecast period because the prevalence of rare diseases among the global population has been increasing in recent years. To tackle this issue, both developing and developed countries have formulated regulations that promote the development of drugs for rare diseases, as well as make sure that these drugs are easily available to the patients.

Currently, the average approval time for non-orphan drugs is around 13 months and the same for orphan drugs is much less at around 10 months. The European Union has implemented similar policies for the development of these drugs and the European governments have individually implemented these policies in their countries. Some of these are Italy's AIFA 5% Fund, Belgium's Special Solidarity Fund, and France's Temporary Authorizations for use.

Even the countries in Asia-Pacific have also followed similar steps with countries like Japan, South Korea, and Taiwan with initiatives like the Revised Orphan Drug Regulations and Orphan Drugs Guidelines (2003). These initiatives offered tax credits and subsidies to both the patient as well as the pharmaceutical companies. These policies in various countries around the world have evolved the market studied, that has been growing at a healthy rate in recent years.

Scope of the Report

Orphan drugs can be defined as a molecule intended to treat a rare disease. The rare disease, as the name suggests, has a low prevalence rate and has been defined differently across geographical locations.

Key Market Trends

Biological Orphan Drug is Expected to Account for the Highest Market Share

In the type of drug segment, biological orphan drug may register the highest market share and is expected to grow at a good pace, during the forecast period. This high market share is due to the higher cost of biological drugs compared to non-biological ones. The recent trend of approval of biological orphan drugs for multiple indication has resulted in growth and has been an encouraging factor for new and established market players to enter in this market. Another reason is that the biological drugs have been used for treating rare disease for a long time. The most focused orphan disease, i.e., cancer, which has a higher prevalence rate in the developed world, has been effectively treated by biological drugs with fewer side effects.

North America Dominates the Market and Expected to do the same in the Forecast Period

North America currently dominates the market for orphan drugs and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. One of the reasons for market growth is that in the United States, a drug designated orphan drug status receives seven years of marketing exclusivity upon FDA approval for a specific indication, tax credits, and user fee waiver. Since 2013, the new indication approvals have increased greatly.

Competitive Landscape

The orphan drugs market is moderately competitive and consists of quite a few major players. In terms of market share, a few of the major players currently dominate the market. With the rising number of diseases and an increasing number of cases each year, a few smaller players are entering the market and holding a substantial share.

Some of the major players of the market are Teva Pharmaceutical Industries Ltd, Celgene, Merck & Co. Inc., Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG, among others.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Market Exclusivity for Orphan Drug Developers
4.2.2 Rising Prevalence of Rare Diseases
4.2.3 Favorable Government Policies
4.3 Market Restraints
4.3.1 High Per Patient Treatment Cost
4.3.2 Limited Patient Pool for Clinical Trials and Product Marketing
4.4 Porter's Five Forces Analysis

5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Biological
5.1.2 Non-Biological
5.2 By Top Selling Drugs
5.2.1 Revlimid
5.2.2 Rituxan
5.2.3 Copaxone
5.2.4 Opdivo
5.2.5 Keytruda
5.2.6 Imbruvica
5.2.7 Avonex
5.2.8 Sensipar
5.2.9 Soliris
5.2.10 Other Top Selling Drugs
5.3 By Disease Type
5.3.1 Oncology
5.3.2 Hematology
5.3.3 Neurology
5.3.4 Cardiovascular
5.3.5 Other Disease Types
5.4 By Phase
5.4.1 Phase I
5.4.2 Phase II
5.4.3 Phase III
5.4.4 Phase IV
5.5 Geography

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie
6.1.2 Celgene Corporation
6.1.3 Biogen
6.1.4 Teva Pharmaceutical Industries
6.1.5 F. Hoffmann-La Roche AG
6.1.6 Bristol-Myers Squibb Company
6.1.7 Alexion Pharmaceuticals
6.1.8 Amgen
6.1.9 Merck & Co. Inc.
6.1.10 Jazz Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/1d7d36

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

22157.jpg


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.